[Pharmacological treatment of spasticity in multiple sclerosis].
The medicinal treatment of spasticity includes use of oral treatments (baclofène and tizanidine), botulinum toxin, intrathecal baclofène and local application of alcohol or phenol. However, spasticity may not be uncomfortable and may even be useful. Therefore, all spastic diseases do not systematically require treatment. First-line treatments (oral treatments and botulinum toxin) can be considered depending on the local or diffuse nature of the spasticity and depending on the etiology.
Service de Neurologie, Hôpital Poissy-Saint-Germain-en-Laye, 20 Rue Armagis, 78100 Saint-Germain-en-Laye, France. olivierheinzlef@yahoo.fr
O
O
Heinzlef
I
I
Monteil-Roch
D000465:Algorithms; D000588:Amines / Q000008:administration & dosage / Q000627:therapeutic use; D001418:Baclofen / Q000008:administration & dosage / Q000627:therapeutic use; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage / Q000627:therapeutic use; D003000:Clonidine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D003509:Cyclohexanecarboxylic Acids / Q000008:administration & dosage / Q000627:therapeutic use; D003620:Dantrolene / Q000008:administration & dosage / Q000627:therapeutic use; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D000077206:Gabapentin; D006801:Humans; D015918:Infusion Pumps, Implantable; D007278:Injections, Spinal; D009103:Multiple Sclerosis / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology / Q000534:rehabilitation; D009125:Muscle Relaxants, Central / Q000008:administration & dosage / Q000627:therapeutic use; D009128:Muscle Spasticity / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology / Q000534:rehabilitation; D009407:Nerve Block; D009465:Neuromuscular Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D013035:Spasm / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D020888:Vigabatrin / Q000008:administration & dosage / Q000627:therapeutic use; D005680:gamma-Aminobutyric Acid / Q000008:administration & dosage / Q000627:therapeutic use
D000588:Amines; D003509:Cyclohexanecarboxylic Acids; D009125:Muscle Relaxants, Central; D009465:Neuromuscular Agents; D005680:gamma-Aminobutyric Acid; C023754:tizanidine; D000077206:Gabapentin; D019274:Botulinum Toxins, Type A; D003620:Dantrolene; D020888:Vigabatrin; D001418:Baclofen; D003000:Clonidine